Every material Form 8-K Envoy Medical, Inc. has filed with the SEC since October 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Envoy Medical reported third-quarter 2026 results for the quarter ended September 30, 2026. Net revenue rose to $66 thousand from $42 thousand, and the net loss attributable to common stockholders narrowed to $5.2 million, or $0.50 per share, from $7.7 million, or $3.55 per share, a year earlier. The company also reported cash of $14.6 million at quarter end, up from $3.7 million at December 31, 2025, and said its pivotal trial of the fully implanted Acclaim cochlear implant has reached the six-month follow-up milestone for all 56 patients.
Net revenue was $66 thousand for the quarter, compared with $42 thousand a year earlier.
Net loss attributable to common stockholders was $5.2 million, or $0.50 per share, versus $7.7 million, or $3.55 per share, in the prior-year quarter.
R&D expenses rose to $3.1 million from $2.7 million, mainly reflecting clinical trial follow-up activity.
On October 6, 2026, the Atlas Merchant Capital litigation was dismissed with prejudice, with no payment by the company.
Envoy Medical (COCH) completed a 1-for-10 reverse stock split, effective 12:01 a.m. Eastern Time on October 26, 2026, and its shares began trading on a post-split basis on the Nasdaq Capital Market that day. The company said the split is intended to maintain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing, and that it may improve trading liquidity.
Stockholders approved the split at a special meeting on October 12, 2026; the board set the ratio at 1-for-10 on the same date, within an approved range of 1-for-5 to 1-for-25.
Every 10 issued and outstanding shares were combined into one share; fractional shares will be paid in cash.
The ticker remains COCH; the new CUSIP number is 29415V307.
The number of authorized shares and the par value per share are unchanged.
Envoy Medical entered a Dismissal Agreement on October 6, 2026, resolving litigation in the Delaware Court of Chancery brought by Atlas Merchant Capital SPAC Fund I LP. Atlas had alleged it was not allowed to redeem its Class A Common Stock in the company's September 2023 business combination. Under the agreement, all Atlas claims will be dismissed with prejudice and neither the company nor any other defendant must make a payment to Atlas.
Agreement dated October 6, 2026, resolves Delaware Court of Chancery litigation with Atlas Merchant Capital SPAC Fund I LP
Atlas's claims will be dismissed with prejudice, with no further proceedings on the Litigation
No payment is required from Envoy Medical or any other defendant to Atlas under the agreement
Filing dated October 7, 2026, signed by CEO Brent Lucas
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Envoy Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →